Is Medicamen Organ. overvalued or undervalued?

As of 18 August 2025, the valuation grade for Medicamen Organ has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE Ratio of 12.81, an EV to EBITDA of 9.73, and a ROE of 21.54%.
In comparison to its peers, Medicamen Organ's PE Ratio is notably lower than that of Sun Pharma, which stands at 34.14, and Divi's Lab, which has a PE Ratio of 70.59. Despite this, the overall valuation suggests that Medicamen Organ is not aligned with its industry peers, many of which are categorized as very expensive or expensive. Furthermore, the company's stock has underperformed significantly, with a year-to-date return of -33.58%, contrasting sharply with the Sensex's positive return of 5.21% during the same period.